CJC-1295 + GHRP-2 (10mg)
Blend of CJC-1295 (long-acting GHRH analog) and GHRP-2 (ghrelin mimetic) in a single 10 mg vial. The GHRH + GHS combination produces synergistic GH pulses significantly stronger than either peptide alone. CJC-1295 increases GH 2–10× for 6–8 days, while GHRP-2 induces rapid GH secretions within ~25 minutes. Administered subcutaneously once daily.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
CJC-1295 is a modified GHRH(1-29) analog with an extended half-life (~6-8 days) via reversible albumin binding (Drug Affinity Complex). It increases GH 2–10× and IGF-1 1.5–3× for 9–11 days post-administration. GHRP-2 (Growth Hormone Releasing Peptide-2) binds to the GHS-R1a receptor (ghrelin receptor), causing acute GH pulses within ~25 minutes. The GHRH + GHS combination yields a **synergistic** (not merely additive) GH secretion, as they act via different receptors on the pituitary gland.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total.
- Typical daily range: 100–300 mcg total (gradual titration over 12 weeks).
- Storage: Lyophilized: 2–8 °C or −20 °C long-term · after reconstitution: 2–8 °C · use within 2–4 weeks.
Gradual Titration (3 mL = ~3.33 mg/mL)
Route: Subcutaneously | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 100 mcg | 3 Units (0.03 mL) |
| Weeks 3–4 | 150 mcg | 4.5 Units (0.04 mL) |
| Weeks 5–6 | 200 mcg | 6 Units (0.06 mL) |
| Weeks 7–12 | 250–300 mcg | 7.5–9 Units (0.07–0.09 mL) |
Studies report administration once daily subcutaneously, preferably in the evening or before bed on an empty stomach (2+ hours after eating). For doses ≤10 units (≤0.10 mL), 30- or 50-unit syringes offer better accuracy.
Reconstitution Steps
- Withdraw 3.0 mL of bacteriostatic water with a sterile syringe.
- Slowly inject down the side of the vial · avoid foaming (do not spray directly onto the powder).
- Gently swirl or rotate until fully dissolved (do not shake violently).
- Note the reconstitution date · refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Goal: Enhanced GH pulses via synergistic GHRH + GHS action in a single vial.
- Schedule: Daily subcutaneous injections for 8–12 weeks, followed by a 4-week break.
- Storage: Lyophilized fridge/freezer · reconstituted fridge · use within 2–4 weeks.
Dosing Protocol
- Start: 100 mcg daily (3 units) to assess tolerance.
- Increase: +50 mcg every 2 weeks: 150 mcg (Wks. 3–4) → 200 mcg (Wks. 5–6).
- Target: 250–300 mcg daily (7.5–9 units) for weeks 7–12.
- Timing: Before bed on an empty stomach (carbohydrates blunt GH response).
- Cycle Duration: 8–12 weeks on, 4 weeks off.
- Break between cycles: A 4–6 week break is recommended after the cycle. The CJC-1295 + GHRP-2 blend provides dual stimulation of GH — the break helps restore receptor sensitivity.
Washout & Cycle Restart
When can I restart?
A 4–6 week break is recommended after the cycle. The CJC-1295 + GHRP-2 blend provides dual stimulation of GH — the break helps restore receptor sensitivity.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: 2–8 °C short-term · −20 °C for long-term storage.
- Reconstituted: Refrigerate at 2–8 °C · use within 2–4 weeks · avoid freeze-thaw cycles.
- Allow frozen vials to reach room temperature before opening.
Important Notes
- Inject on an empty stomach (2+ hours after eating) — carbohydrates/insulin blunt the GH response.
- No PCT is required after discontinuation — endogenous GH production recovers naturally.
Potential Benefits & Side Effects
Potential Benefits:
- Sustained increase in GH and IGF-1 (6–11 days per CJC-1295 dose).
- Synergistic GH pulses significantly stronger than single-agent use.
- Improved body composition (muscle mass ↑, body fat ↓).
- Support for recovery, sleep quality, and skin health.
- Well-tolerated in clinical studies.
Potential Side Effects:
- Transient increase in appetite (ghrelin action via GHRP-2) — especially initially.
- Mild increases in ACTH/cortisol (within physiological ranges, unlike Ipamorelin).
- Transient flushing/redness at high doses.
- Mild injection site reaction (redness, itching).
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Increased cortisol & prolactin (less than GHRP-6)
Less ghrelin-hunger than GHRP-6, but still increases cortisol. Long-term effects on HPA axis unclear.
📄 J Clin Endocrinol Metab 1997References
- J Clin Endocrinol Metab — CJC-1295: prolonged increase in GH/IGF-1 via DAC technology
View Source - Endocrine Reviews — GHRP-2: clinical applications of GH secretagogues
View Source - Growth Hormone & IGF Research — Synergistic action of GHRH + GHRP on GH secretion
View Source - Transl Androl Urol (PMC) — GH secretagogues in body composition: a review
View Source
External Sources & Regulatory Status
Regulatory Approvals
GHRP Kaken® · GH deficiency diagnostic (2008)
Approved in Japan (diagnostic)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →